Aclaris Therapeutics Inc. Common Stock (ACRS)

About ACRS

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with n…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

69

Website

www.aclaristx.com/

Fundamentals

1-day range

$5.95$6.17

Market cap

$850.55M

P/E (trailing)

—

P/E (forward)

-7.40

EPS (trailing)

$-0.59

Dividend yield

—

Beta

0.88

Avg. volume

1.90M

Forecasts

10 analyst ratings

Aclaris Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ACRS

  Aclaris Therapeutics Inc. Common Stock

  $6.01

  ▼ 2.44%
  Market cap $850.55MP/E —
  $1.74$6.6
• DSGN

  Design Therapeutics Inc. Common Stock

  $15.12

  ▼ 0.85%
  Market cap $861.75MP/E —
  $5.04$17.25
• AMPH

  Amphastar Pharmaceuticals Inc. Common Stock

  $22.01

  ▲ 0.59%
  Market cap $873.48MP/E 10.93
  $16.65$31.26
• KURA

  Kura Oncology Inc. Common Stock

  $12.65

  ▼ 4.06%
  Market cap $823.83MP/E —
  $7.36$13.9
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $805.29MP/E —
  $32.77$124.82
• CLYM

  Climb Bio Inc. Common Stock

  $14.56

  ▼ 3.32%
  Market cap $801.68MP/E —
  $1.54$18.33
• DRUG

  Bright Minds Biosciences Inc. Common Stock

  $72.74

  ▼ 2.41%
  Market cap $792.81MP/E —
  $53.99$170

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Vipshop, Gorilla Technology Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
  Benzinga · 8/25/2026
• Why Cadeler Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
  Benzinga · 8/25/2026
• Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
  Benzinga · 8/25/2026
• Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate
  Benzinga · 8/6/2026

• Kolbeck Roland Wilhelm · August 1, 2026 · Option Exercise

  36.4K
• Kolbeck Roland Wilhelm · August 1, 2026 · Tax Withholding

  12.4K @ $5.2
• Humphries William D. · June 5, 2026 · Option Exercise

  11.6K
• Molineaux Christopher P. · June 5, 2026 · Option Exercise

  11.6K
• Mehra Anand · June 5, 2026 · Option Exercise

  11.6K
• GOWEN MAXINE · June 5, 2026 · Option Exercise

  11.6K
• Vincent Milano · June 5, 2026 · Option Exercise

  11.6K
• SCHIFF ANDREW N · June 5, 2026 · Option Exercise

  11.6K
• Humphries William D. · June 4, 2026 · Grant

  11.0K
• Humphries William D. · June 4, 2026 · Grant

  42.4K
• Molineaux Christopher P. · June 4, 2026 · Grant

  11.0K
• Molineaux Christopher P. · June 4, 2026 · Grant

  42.4K
• Mehra Anand · June 4, 2026 · Grant

  11.0K
• Mehra Anand · June 4, 2026 · Grant

  42.4K
• GOWEN MAXINE · June 4, 2026 · Grant

  11.0K

Institutional Ownership

March 31, 2026

Total shares held

106.74M

Total value held

$392.03M

Institutional holders

132